Cargando…
Immunization against Haemophilus Influenzae Type b in Iran; Cost-utility and Cost-benefit Analyses
BACKGROUND: Haemophilus Influenzae type b (Hib) is an important cause of morbidity and mortality in children. Although its burden is considerably preventable by vaccine, routine vaccination against Hib has not been defined in the National Immunization Program of Iran. This study was performed to ass...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372076/ https://www.ncbi.nlm.nih.gov/pubmed/22708030 |
_version_ | 1782235317916401664 |
---|---|
author | Moradi-Lakeh, Maziar Shakerian, Sareh Esteghamati, Abdoulreza |
author_facet | Moradi-Lakeh, Maziar Shakerian, Sareh Esteghamati, Abdoulreza |
author_sort | Moradi-Lakeh, Maziar |
collection | PubMed |
description | BACKGROUND: Haemophilus Influenzae type b (Hib) is an important cause of morbidity and mortality in children. Although its burden is considerably preventable by vaccine, routine vaccination against Hib has not been defined in the National Immunization Program of Iran. This study was performed to assess the cost-benefit and cost-utility of running an Hib vaccination program in Iran. METHODS: Based on a previous systematic review and meta-analysis for vaccine efficacy, we estimated the averted DALYs (Disability adjusted life years) and cost-benefit of vaccination. Different acute invasive forms of Hib infection and the permanent sequels were considered for estimating the attributed DALYs. We used a societal perspective for economic evaluation and included both direct and indirect costs of alternative options about vaccination. An annual discount rate of 3% and standard age-weighting were used for estimation. To assess the robustness of the results, a sensitivity analysis was performed. RESULTS: The incidence of Hib infection was estimated 43.0 per 100000, which can be reduced to 6.7 by vaccination. Total costs of vaccination were estimated at US$ 15,538,129. Routine vaccination of the 2008 birth cohort would prevent 4079 DALYs at a cost per averted-DALY of US$ 4535. If we consider parents’ loss of income and future productivity loss of children, it would save US$ 8,991,141, with a benefit-cost ratio of 2.14 in the base-case analysis. Sensitivity analysis showed a range of 0.78 to 3.14 for benefit-to-cost ratios. CONCLUSION: Considering costs per averted DALY, vaccination against Hib is a cost-effective health intervention in Iran, and allocating resources for routine vaccination against Hib seems logical. |
format | Online Article Text |
id | pubmed-3372076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-33720762012-06-15 Immunization against Haemophilus Influenzae Type b in Iran; Cost-utility and Cost-benefit Analyses Moradi-Lakeh, Maziar Shakerian, Sareh Esteghamati, Abdoulreza Int J Prev Med Original Article BACKGROUND: Haemophilus Influenzae type b (Hib) is an important cause of morbidity and mortality in children. Although its burden is considerably preventable by vaccine, routine vaccination against Hib has not been defined in the National Immunization Program of Iran. This study was performed to assess the cost-benefit and cost-utility of running an Hib vaccination program in Iran. METHODS: Based on a previous systematic review and meta-analysis for vaccine efficacy, we estimated the averted DALYs (Disability adjusted life years) and cost-benefit of vaccination. Different acute invasive forms of Hib infection and the permanent sequels were considered for estimating the attributed DALYs. We used a societal perspective for economic evaluation and included both direct and indirect costs of alternative options about vaccination. An annual discount rate of 3% and standard age-weighting were used for estimation. To assess the robustness of the results, a sensitivity analysis was performed. RESULTS: The incidence of Hib infection was estimated 43.0 per 100000, which can be reduced to 6.7 by vaccination. Total costs of vaccination were estimated at US$ 15,538,129. Routine vaccination of the 2008 birth cohort would prevent 4079 DALYs at a cost per averted-DALY of US$ 4535. If we consider parents’ loss of income and future productivity loss of children, it would save US$ 8,991,141, with a benefit-cost ratio of 2.14 in the base-case analysis. Sensitivity analysis showed a range of 0.78 to 3.14 for benefit-to-cost ratios. CONCLUSION: Considering costs per averted DALY, vaccination against Hib is a cost-effective health intervention in Iran, and allocating resources for routine vaccination against Hib seems logical. Medknow Publications & Media Pvt Ltd 2012-05 /pmc/articles/PMC3372076/ /pubmed/22708030 Text en Copyright: © International Journal of Preventive Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Moradi-Lakeh, Maziar Shakerian, Sareh Esteghamati, Abdoulreza Immunization against Haemophilus Influenzae Type b in Iran; Cost-utility and Cost-benefit Analyses |
title | Immunization against Haemophilus Influenzae Type b in Iran; Cost-utility and Cost-benefit Analyses |
title_full | Immunization against Haemophilus Influenzae Type b in Iran; Cost-utility and Cost-benefit Analyses |
title_fullStr | Immunization against Haemophilus Influenzae Type b in Iran; Cost-utility and Cost-benefit Analyses |
title_full_unstemmed | Immunization against Haemophilus Influenzae Type b in Iran; Cost-utility and Cost-benefit Analyses |
title_short | Immunization against Haemophilus Influenzae Type b in Iran; Cost-utility and Cost-benefit Analyses |
title_sort | immunization against haemophilus influenzae type b in iran; cost-utility and cost-benefit analyses |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3372076/ https://www.ncbi.nlm.nih.gov/pubmed/22708030 |
work_keys_str_mv | AT moradilakehmaziar immunizationagainsthaemophilusinfluenzaetypebinirancostutilityandcostbenefitanalyses AT shakeriansareh immunizationagainsthaemophilusinfluenzaetypebinirancostutilityandcostbenefitanalyses AT esteghamatiabdoulreza immunizationagainsthaemophilusinfluenzaetypebinirancostutilityandcostbenefitanalyses |